Search Results | Blood | American Society of Hematology

1-20 of 400

Sort by

Sort Order Select

Journal Articles

Foamy Virus Based Vectors for CAR-T Cell Development

Emmanouil Simantirakis, MSc, Vassilis Atsaves, PhD, Ioannis Tsironis, BSc MSc, Margarita Gkyzi, BSc, Kostas Konstantopoulos, MD PhD, George Vassilopoulos, MD PhD

Blood (2019) 134 (Supplement_1): 4646.

DOI: https://doi.org/10.1182/blood-2019-123022

Published: 2019

Journal Articles

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Christine Burnett, Gary Gordon, MD PhD, Thomas Strack, MD, Tara Lehner, MS, PMP, Jack P Higgins, PhD, Jason Tache, DO

Blood (2019) 134 (Supplement_1): 1597.

DOI: https://doi.org/10.1182/blood-2019-128503

Published: 2019

Journal Articles

High Avidity IgM-Based CD20xCD3 Bispecific Antibody (IGM-2323) for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release

Ramesh Baliga, PhD, Keyu Li, PhD, Marigold Manlusoc, Paul Hinton, Dean Ng, PhD, Madeline Tran, Bing Shan, PhD, Hai Lu, Avneesh Saini, PhD, Sachi Rahman, Yuan Cao, PhD, Chitra Saraiya, Marvin Peterson, PhD, Steve Carroll, PhD, Daniel Chen, MD PhD, Bruce Keyt, PhD

Blood (2019) 134 (Supplement_1): 1574.

DOI: https://doi.org/10.1182/blood-2019-131650

Published: 2019

Journal Articles

A Novel Revcar Platform for Switchable and Gated Tumor Targeting

Anja Feldmann, PhD, Anja Hoffmann, Enrico Kittel-Boselli, Ralf Bergmann, PhD, Stefanie Koristka, PhD, Nicole Berndt, PhD, Claudia Arndt, PhD, Liliana Raquel Loureiro, PhD, Nicola Mitwasi, Justyna Jureczek, Martin Bornhaeuser, MD, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5611.

DOI: https://doi.org/10.1182/blood-2019-128436

Published: 2019

Journal Articles

Development of Novel Anti-CD10 Target Modules for Redirection of Universal CAR T Cells Against CD10-Positive Malignancies

Anja Feldmann, PhD, Stefanie Koristka, PhD, Claudia Arndt, PhD, Liliana Raquel Loureiro, PhD, Ralf Bergmann, PhD, Nicole Berndt, PhD, Anja Hoffmann, Justyna Jureczek, Nicola Mitwasi, Martin Bornhaeuser, MD, Václav Hořejší, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5612.

DOI: https://doi.org/10.1182/blood-2019-128193

Published: 2019

Journal Articles

Targeting the FMS-like Tyrosin Kinase 3 with the Unicar System: Preclinical Comparison of Murine and Humanized Single-Chain Variable Fragment-Based Targeting Modules

Frederick Fasslrinner, MD, Claudia Arndt, PhD, Anja Feldmann, PhD, Stefanie Koristka, PhD, Liliana Raquel Loureiro, PhD, Marc Schmitz, MD, Gundram Jung, MD, Martin Bornhaeuser, MD, Michael Bachmann, MD

Blood (2019) 134 (Supplement_1): 5614.

DOI: https://doi.org/10.1182/blood-2019-124279

Published: 2019

Journal Articles

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Zachary Davis, PhD BS, Martin Felices, PhD, Todd R Lenvik, Sujan Badal, Peter Hinderlie, Bruce R. Blazar, MD, Daniel A. Vallera, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 621.

DOI: https://doi.org/10.1182/blood-2019-127261

Published: 2019

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

Jeffrey Teoh, PhD, Timothy G. Johnstone, PhD, Brian Christin, BS, Rachel Yost, Neil A. Haig, Mary Mallaney, Aditya Radhakrishnan, Heidi H. Gillenwater, MD, Tina Albertson, MD, Paul Guptill, Lauren F. Brown, Christopher G. Ramsborg, Ronald J. Hause, PhD, Ryan P. Larson, PhD

Blood (2019) 134 (Supplement_1): 593.

DOI: https://doi.org/10.1182/blood-2019-127150

Published: 2019

Journal Articles

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Chunrui Li, MD PhD, Jue Wang, MD PhD, Di Wang, MD PhD, Guang Hu, Yongkun Yang, Xiaoxi Zhou, MD PhD, Li Meng, MD PhD, Zhenya Hong, MD PhD, Liting Chen, PhD, Xia Mao, MD PhD, Min Xiao, MD PhD, Jianfeng Zhou, MD PhD

Blood (2019) 134 (Supplement_1): 929.

DOI: https://doi.org/10.1182/blood-2019-128468

Published: 2019

Journal Articles

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

Blood (2019) 134 (Supplement_1): 744.

DOI: https://doi.org/10.1182/blood-2019-129411

Published: 2019

Journal Articles

A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

Chenggong Li, Heng Mei, Yu Hu, MD PhD, Tao Guo, MD PhD, Lin Liu, MD PhD, Huiwen Jiang, Lu Tang, Yaohui Wu, MD PhD, Lisha Ai, MD PhD, Jun Deng, MD PhD, Dan Jin

Blood (2019) 134 (Supplement_1): 930.

DOI: https://doi.org/10.1182/blood-2019-130340

Published: 2019

Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD

Blood (2019) 134 (Supplement_1): 1867.

DOI: https://doi.org/10.1182/blood-2019-125629

Published: 2019

Journal Articles

Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

Maria Karvouni, MSc, PharmD, Heyue Zhou, Arnika Kathleen Wagner, PhD, Qiangzhong Ma, Alamdar H. Baloch, PhD, Tong Zhu, Hong Zhang, Mari Gilljam, Andreas Lundqvist, PhD, Gunnar F. Kaufmann, PhD, Evren Alici, MD PhD

Blood (2019) 134 (Supplement_1): 1848.

DOI: https://doi.org/10.1182/blood-2019-127893

Published: 2019

Journal Articles

Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 50.

DOI: https://doi.org/10.1182/blood-2019-125372

Published: 2019

Journal Articles

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

Satoru Aoyama, MD, Shunichiro Yasuda, MD, Daisuke Watanabe, MD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD PhD BPharm, Osamu Miura, MD, PhD, Norihiko Kawamata, MD, PhD

Blood (2019) 134 (Supplement_1): 1941.

DOI: https://doi.org/10.1182/blood-2019-121973

Published: 2019

Journal Articles

A Novel Platelet-Targeting Fibrinolytic Strategy: Endocytosed Urokinase By Megakaryocytes Is Stored in α-Granules and Is Functional In Vivo in a Murine Model of Thrombosis

Hyunsook Ahn, MSc, John Tkaczynski, BS, Khalil Bdeir, PhD, Victoria Stepanova, Douglas B. Cines, MD, Mortimer Poncz, MD, Sergei Zaitsev

Blood (2019) 134 (Supplement_1): 3627.

DOI: https://doi.org/10.1182/blood-2019-124501

Published: 2019

Journal Articles

Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase

Damian J. Green, MD, Margot Pont, PhD, Andrew J. Cowan, MD, Gabriel O Cole, Blythe Duke Sather, PhD, Anne M Nagengast, RN, Xaoling Song, Sushma Thomas, Brent L Wood, MD PhD, Michelle L Blake, PhD, Melissa G Works, PhD, Ted A Gooley, PhD, David G. Maloney, MD PhD, Stanley R. Riddell, MD

Blood (2019) 134 (Supplement_1): 1856.

DOI: https://doi.org/10.1182/blood-2019-129582

Published: 2019

Journal Articles

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

Blood (2019) 134 (Supplement_1): 1949.

DOI: https://doi.org/10.1182/blood-2019-131546

Published: 2019

Journal Articles

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Jeong A Park, MD PhD, Hong fen Guo, PhD, Hong Xu, PhD, Nai-Kong V. Cheung, MD PhD

Blood (2019) 134 (Supplement_1): 1959.

DOI: https://doi.org/10.1182/blood-2019-131325

Published: 2019

Journal Articles

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

Jode P Goodridge, PhD, Sajid Mahmood, PhD, Huang Zhu, PhD, Svetlana Gaidarova, MS, Robert Blum, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 301.

DOI: https://doi.org/10.1182/blood-2019-129319

Published: 2019

NARROW

Foamy Virus Based Vectors for CAR-T Cell Development

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Lenalidomide in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

High Avidity IgM-Based CD20xCD3 Bispecific Antibody (IGM-2323) for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release

A Novel Revcar Platform for Switchable and Gated Tumor Targeting

Development of Novel Anti-CD10 Target Modules for Redirection of Universal CAR T Cells Against CD10-Positive Malignancies

Targeting the FMS-like Tyrosin Kinase 3 with the Unicar System: Preclinical Comparison of Murine and Humanized Single-Chain Variable Fragment-Based Targeting Modules

PD-1 Is Expressed at Low Levels on All Peripheral Blood Natural Killer Cells but Is a Significant Suppressor of NK Function Against PD-1 Ligand Expressing Tumor Targets

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL)

A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial

Ex Vivo Activity of Immunotherapeutic Approaches Targeting CD38 Against Daratumumab-Resistant Multiple Myeloma Patient Samples

Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma

A Novel Protease-Mediated Chimeric Antigen Receptor (CAR): "Double-Arm" CAR-T Cell System Improves Target Specificity of CAR-T Cell Therapy

A Novel Platelet-Targeting Fibrinolytic Strategy: Endocytosed Urokinase By Megakaryocytes Is Stored in α-Granules and Is Functional In Vivo in a Murine Model of Thrombosis

Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma Secretase

Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only